California
Biotech Insights

Recent Funding: Ray Therapeutics (SF) Raises $125 Million to Advance Gene Therapy for Vision Loss Ray Therapeutics closed an oversubscribed Series B round led by Janus Henderson Investors to fund its lead gene therapy RTx-015, which aims to restore vision in patients with retinitis pigmentosa — a genetic disease that progressively destroys the cells in […]

Recent Funding: Neomorph (SD) Closes $100M Series B Led by Deerfield to Advance Molecular Glue Degrader Platform and NEO-811 Kidney Cancer Trial Neomorph closed $100 million Series B led by Deerfield Management with participation from new investors Regeneron Ventures, Longwood Fund, Alexandria Venture Investments, Binney Street Capital of Dana-Farber Cancer Institute, and others. Proceeds will […]

Recent Funding: Sidewinder Therapeutics (SD) Raises $137M Series B to Develop Bispecific ADCs with Reduced Toxicity Sidewinder Therapeutics (7 employees, co-founded by Harvard scientist Ryan Corcoran and CEO Eric Murphy) raised $137 million Series B ($162 million total raised) led by OrbiMed, with Frazier Life Sciences, Goldman Sachs Alternatives, DCVC Bio, Samsara BioCapital, Longwood Fund, […]

M&A, Deals, Partnerships: Aurinia Pharmaceuticals Acquires Kezar Life Sciences (SF) for ~$50M After Tang’s 2024 Bid Rejected Aurinia Pharmaceuticals (led by new CEO Kevin Tang as of last week) is acquiring South San Francisco-based Kezar Life Sciences for $6.95 cash per share (~$50 million total) plus a contingent value right (CVR) tied to future development […]

Recent Funding: Triangle Health (CA) Raises $4M for AI Health Assistant to Help Patients Navigate Medical Care Triangle Health raised $4 million led by SNR.vc to build an AI assistant that helps patients understand health conditions and explore treatment options by analyzing their complete medical history. The platform can brainstorm treatments, prepare doctor appointment questions, […]

Recent Funding: R1 Therapeutics (SF) Raises $77.5M Series A to Develop Once-Daily Pill for Kidney Disease Patients on Dialysis R1 Therapeutics launched with $77.5 million to develop AP306, a once-daily pill for hyperphosphatemia (high phosphate levels) in chronic kidney disease patients on dialysis. Unlike existing treatments that require patients to take 3-5 pills per meal […]